Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Israel-Rosen who wrote (1370)	10/9/1998 8:53:00 PM
From: yosi s	Read Replies (1) of 1491

David my take on the release is three fold. 1. the decrease in ICP is very important. and is not due to chance. It is consistent with the model of how hu211 works. but what is the most important is... 2. Clinically those patients that were severly affected . Being very sick but not dying nor comatose. showed the best improvement. or as Said by their chief investigator, the improvement was in all the LEVELS BUT SEEN BEST IN THE MODERATE TO SEVERE. Now that is wht I have a good degree of confidence that phase 3 will prove what phase 2 showed. In a small sample. you can see best where the difference is most. and that is exactly what happened. So if this is due to random events there are just too many things that follow a pattern. 3. Safety issue there is none. it is safer then placebo. Blood Pressure is better maintained. this may also play in mechanisme of action. or it may be that it counter acts Alpha TNF. THIS is worthwhile looking into. IT MAY BE BIGGER THAN BRAIN INJURY ALONE. Until this is well understood we will complain about the price.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next